HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission.

AbstractBACKGROUND:
Consensus regarding the cutoff value of fecal calprotectin (FC) for predicting histological healing (HH) in ulcerative colitis (UC) is lacking. This study aimed to determine an optimal FC cutoff value for predicting HH in patients with UC with clinical and endoscopic remission. Furthermore, FC's predictability for prolonged clinical remission (CR) was investigated.
METHODS:
Patients with UC in clinical and endoscopic remission, defined as a partial Mayo score (PMS) ≤ 2 points and a Mayo endoscopic subscore 0-1, were prospectively enrolled. Biopsy samples were evaluated by Geboes score (GS), with HH defined as a GS < 2.0. Patients were followed for 2 years or until relapse, defined as a PMS > 2 or medication escalation.
RESULTS:
Seventy-six patients with UC were included. The median FC value in patients with HH (n = 40) was 56.2 µg/g, significantly lower than that in those with histological activity (118.1 µg/g; P < .01). The area under the curve (AUC) in a receiver operating characteristic (ROC) curve analysis to predict HH for FC was 0.71 (95% confidence interval [CI], 0.59-0.83), with an optimal cutoff value of 82.7 µg/g (73% sensitivity; 64% specificity; P < .01). Of 74 patients observed for 2 years, 54 (73%) had prolonged CR. In the ROC curve analysis, the AUC to predict prolonged CR for FC was 0.79 (95% CI, 0.68-0.90), equivalent to that for HH (0.73; 95% CI, 0.64-0.86; P = .40). The optimal FC cutoff value to predict prolonged CR was 84.6 µg/g (72% sensitivity; 85% specificity; P < .01).
CONCLUSIONS:
Fecal calprotectin < 82 µg/g predicts HH in patients with UC with clinical and endoscopic remission. Low FC leads to prolonged CR, equivalent to HH.
AuthorsKousaku Kawashima, Naoki Oshima, Kenichi Kishimoto, Masatoshi Kataoka, Mai Fukunaga, Satoshi Kotani, Hiroki Sonoyama, Akihiko Oka, Yoshiyuki Mishima, Hideaki Kazumori, Noriyoshi Ishikawa, Asuka Araki, Shunji Ishihara
JournalInflammatory bowel diseases (Inflamm Bowel Dis) Vol. 29 Issue 3 Pg. 359-366 (03 01 2023) ISSN: 1536-4844 [Electronic] England
PMID35583193 (Publication Type: Journal Article)
Copyright© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: [email protected].
Chemical References
  • Leukocyte L1 Antigen Complex
  • Biomarkers
Topics
  • Humans
  • Colitis, Ulcerative (drug therapy)
  • Colonoscopy
  • Leukocyte L1 Antigen Complex (analysis)
  • Biomarkers (analysis)
  • ROC Curve
  • Feces (chemistry)
  • Remission Induction
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: